CC-10004

Curr Opin Investig Drugs. 2005 May;6(5):518-25.

Abstract

CC-10004, a phosphodiesterase 4 inhibitor and selective cytokine inhibitor, is under development by Celgene for the potential treatment of asthma, chronic obstructive pulmonary disease, inflammation and psoriasis. By October 2004, phase II trials in psoriasis had commenced.

Publication types

  • Review

MeSH terms

  • 3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors*
  • 3',5'-Cyclic-AMP Phosphodiesterases / pharmacology
  • 3',5'-Cyclic-AMP Phosphodiesterases / therapeutic use*
  • Animals
  • Asthma / drug therapy
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • Cytokines / antagonists & inhibitors*
  • Cytokines / pharmacology
  • Cytokines / therapeutic use*
  • Dose-Response Relationship, Drug
  • Humans
  • Phosphodiesterase Inhibitors / administration & dosage
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Psoriasis / drug therapy
  • Pulmonary Disease, Chronic Obstructive / drug therapy

Substances

  • Cytokines
  • Phosphodiesterase Inhibitors
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 4